financetom
Business
financetom
/
Business
/
Ackman at Milken says Harvard is not 'entitled' to federal funds
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ackman at Milken says Harvard is not 'entitled' to federal funds
May 26, 2025 2:18 AM

*

Ackman criticizes Harvard's financial management and

investment

policies

*

Trump admin freezes future grants to Harvard

*

Ackman says Harvard's tax exemptions at risk due to

mismanagement

*

He suggests faculty and students could relocate

By Svea Herbst-Bayliss

BEVERLY HILLS, May 6 (Reuters) - Billionaire investor

Bill Ackman on Tuesday said Harvard University, one of the

nation's oldest and wealthiest, should not be entitled to

taxpayer funds when the school wastes money on what he calls

"administrative bloat."

Ackman, who earned undergraduate and business degrees from

Harvard more than three decades ago, was speaking hours after

the Trump administration said it was freezing future grants to

Harvard.

He also criticized the school's investment policies, saying

the Ivy League university is facing a financial crisis and that

its $53 billion endowment is "poorly invested."

"They have lost all future grants, their tax exemptions are

at risk," Ackman said on a panel at the Milken Institute Global

Conference where 5,000 financiers, educators and scientists

gather to discuss critical issues of the day.

"It is all self-induced gross mismanagement and I think that

the (Trump) administration is doing precisely the right thing

now," Ackman told the packed room.

The U.S. Department of Education informed Harvard on Monday

that it was freezing billions of dollars in future research

grants and other aid until the university concedes to a number

of demands from the Trump administration, a senior department

official said.

Harvard responded that the administration letter doubles

down on demands that would impose "unprecedented and improper

control" over the university and makes new threats to

"illegally" withhold funding for lifesaving research.

"The notion is the federal government money is only going to

fund breakthrough research, that is just false," Ackman said.

A representative for the university was not immediately

available for comment and a representative for Harvard

Management Company, which invests the endowment, declined to

comment.

Ackman has long been at odds with Harvard, criticizing the

university for not doing enough to protect students from

antisemitism. Early last year he launched an unsuccessful bid to

get four candidates on the ballot for a governing board.

The financier runs New York-based hedge fund firm Pershing

Square Capital Management and has been a vocal supporter of

Trump's policies on tariffs and spending. Harvard is "a

collection of buildings, nice real estate" located in Cambridge,

Massachusetts next to the Charles River, he said.

But its cutting-edge faculty, researchers and students could

easily move elsewhere, he said. "This is the best time in

history to start a university."

He also again hit out at the school's governing board,

saying it has become insular and that there is no mechanism to

remove members the way there is in corporate America where

investors can run board challenges.

"What happens when you have a board that can self-appoint

itself, and it becomes insular, and with a $53 billion

endowment, they think, okay, we can just do whatever is on our

mind."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved